{"id":12446,"date":"2024-06-06T08:22:22","date_gmt":"2024-06-06T06:22:22","guid":{"rendered":"https:\/\/www.cilcare.com\/?p=12446"},"modified":"2024-06-06T08:20:07","modified_gmt":"2024-06-06T06:20:07","slug":"cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment","status":"publish","type":"post","link":"https:\/\/www.cilcare.com\/jp\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/","title":{"rendered":"Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"12446\" class=\"elementor elementor-12446\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-22a8dcc7 e-flex e-con-boxed e-con e-parent\" data-id=\"22a8dcc7\" data-element_type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-793a1fd6 elementor-widget elementor-widget-text-editor\" data-id=\"793a1fd6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong><u>Montpellier and Osaka \u2013 June 6<span style=\"font-size: 13.3333px;\">th<\/span>, 2024<\/u><\/strong><strong> \u2013 <\/strong><strong><em>Cilcare<\/em><\/strong><strong>, a leading biotech company specializing in auditory sciences, is pleased to announce a landmark agreement with <em>Shionogi<\/em>, an impact-driven pharmaceutical company. This exclusive option agreement grants Shionogi the right to license global rights to CIL001 and<\/strong><strong>\/or<\/strong><strong> CIL003, two promising drug candidates aimed at treating hearing disorders, with a particular focus on addressing the increasing prevalence of hidden hearing loss and tinnitus.<\/strong><\/p><p><strong>Under the terms of the agreement:<\/strong><\/p><ul><li><strong>Shionogi will receive an exclusive option to license global rights to CIL001 and\/or CIL003.<\/strong><\/li><li><strong>Cilcare will receive an upfront payment of \u20ac15 million.<\/strong><\/li><li><strong>Cilcare is eligible to receive up to \u20ac400 million in milestone payments upon successful development and commercialization of the drug candidates.<\/strong><\/li><li><strong>Shionogi will decide whether to exercise the option right based on the results of the Phase 2a studies of CIL001 and preclinical study data of CIL003, both to be conducted by Cilcare.<\/strong><\/li><\/ul><p>Driven by its pioneering approaches from preclinical research to drug development, which harness <strong>AI-driven auditory markers<\/strong> known as Digital Auditory Signatures, Cilcare is dedicated to advancing therapies for auditory-related diseases. The agreement with Shionogi underscores Cilcare&#8217;s commitment to <strong>\u5916\u90e8\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3<\/strong> and collaboration to address critical unmet needs in hearing disorders.<\/p><p><strong>CIL001<\/strong>, a disease-modifying small molecule, holds promise for treating <strong>\u8778\u725b\u30b7\u30ca\u30d7\u30b9\u969c\u5bb3<\/strong> \u306e\u4e88\u9632\u304a\u3088\u3073\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305f\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3092\u652f\u63f4\u3057\u3066\u3044\u307e\u3059\u3002 <strong>associated disorders<\/strong> through a single and painless transtympanic administration. Supported by <strong>robust preclinical and clinical safety data<\/strong>, CIL001 is poised to enter Phase 2a trials in 2025 in Europe and United States of America. Additionally, preclinical studies for <strong>CIL003<\/strong> are currently underway.<\/p><p><strong>Celia Belline<\/strong>, <strong>CEO of Cilcare<\/strong>, expressed her pride in the recognition of Cilcare&#8217;s expertise by a global pharmaceutical leader. She emphasized the partnership&#8217;s potential to expand the pipeline and drive innovation in hearing disease therapeutics.<\/p><p><strong>Shionogi<\/strong> echoed <strong>Cilcare&#8217;s<\/strong> enthusiasm for the partnership, citing the alignment with their strategic focus on improving global health and well-being.<\/p><p><strong>Hearing loss<\/strong> affects approximately 1.5 billion people worldwide, with <strong>hidden hearing loss<\/strong>, or <a href=\"https:\/\/www.cilcare.com\/jp\/cochlear-synaptopathy\/\"><strong>\u8778\u725b\u30b7\u30ca\u30d7\u30b9\u969c\u5bb3<\/strong><\/a>, emerging as a significant challenge despite normal hearing tests. This condition, affecting about <strong>15% of the population<\/strong>, underscores the urgent need for innovative therapies to address <strong>speech comprehension difficulties<\/strong> and other associated symptoms.<\/p><p>The collaboration between <strong>Cilcare<\/strong> \u306e\u4e88\u9632\u304a\u3088\u3073\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305f\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3092\u652f\u63f4\u3057\u3066\u3044\u307e\u3059\u3002 <strong>Shionogi<\/strong> represents a pivotal step in addressing the urgent global health crisis posed by hearing disorders, offering hope for millions of individuals worldwide.<\/p><p>For this option agreement,\u00a0Cilcare was advised by <a href=\"https:\/\/agilecapitalmarkets.com\/\">Agile Capital Markets<\/a> \u306e\u4e88\u9632\u304a\u3088\u3073\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305f\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3092\u652f\u63f4\u3057\u3066\u3044\u307e\u3059\u3002 <a href=\"https:\/\/www.mwe.com\/\">McDermott Will &amp; Emery<\/a>.<\/p><ul><li>For media inquiries, please contact:<\/li><\/ul><p>Marie Peytavy, Marketing &amp; Communication Director: <strong><a href=\"mailto:marie.peytavy@cilcare.com\">marie.peytavy@cilcare.com<\/a><\/strong><\/p><ul><li>For investor relations, please contact: <strong><a href=\"mailto:investors@cilcare.com\">investors@cilcare.com<\/a><\/strong><\/li><\/ul><p><strong><u>About Cilcare Development<\/u><\/strong><\/p><p><strong>Cilcare<\/strong> is a biotech established in 2014, dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. Cilcare\u2019s mission is to ensure hearing impairments are addressed earlier and with precision, as they are often associated with chronic diseases from their very early stages. As a catalyst in the development of pharmaceuticals, medical devices, gene therapies, and cell therapies for hearing loss and tinnitus, Cilcare is driving transformative breakthroughs.<\/p><p><strong><u>About Shionogi Ltd.<\/u><\/strong><\/p><p>Shionogi &amp; Co., Ltd. is a leading global research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of &#8220;<em>Supplying the best possible medicine to protect the health and well-being of the patients we serve<\/em>.&#8221; Shionogi has discovered and developed novel antibiotics, medicines for HIV and influenza and currently markets medicines for infectious diseases and central nervous system disorders. Shionogi\u2019s global pipeline includes research programs in infectious disease, pain\/CNS, metabolic disorders, rare disease, oncology and stroke.<\/p><p>For more information, visit <strong><a href=\"https:\/\/www.shionogi.com\/global\/en\/\">Shionogi&#8217;s website<\/a><\/strong><\/p><p><strong><u>About CIL001<\/u><\/strong><\/p><p><strong>CIL001<\/strong> is a novel candidate drug for hearing loss treatment with <strong>auditory nerve protective effect<\/strong>. In preclinical studies to date, CIL001 has been confirmed to have an organic effect that repairs inner ear cochlear synapses, and a functional effect that improves the first wave of the auditory brainstem response (ABR).<\/p><p><strong><a href=\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Cilcare-Shionogi_Option-agreement_6June2024.pdf\">Download Press Release (<em>English version<\/em>)<\/a><\/strong><\/p><p><strong><a href=\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/CP_Cilcare-Shionogi_6Juin2024.pdf\">Download Press Release (<em>French version<\/em>)<\/a><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Montpellier and Osaka \u2013 June 6th, 2024 \u2013 Cilcare, a leading biotech company specializing in auditory sciences, is pleased to announce a landmark agreement with Shionogi, an impact-driven pharmaceutical company. This exclusive option agreement grants Shionogi the right to license global rights to CIL001 and\/or CIL003, two promising drug candidates aimed at treating hearing disorders, with a particular focus on addressing the increasing prevalence of hidden hearing loss and tinnitus. Under the terms of the agreement: Shionogi will receive an exclusive option to license global rights to CIL001 and\/or CIL003. Cilcare will receive an upfront payment of \u20ac15 million. Cilcare is eligible to receive up to \u20ac400 million in milestone [&hellip;]<\/p>","protected":false},"author":6,"featured_media":12452,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[114],"tags":[],"class_list":["post-12446","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","entry","has-media"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment - Cilcare<\/title>\n<meta name=\"description\" content=\"Cilcare and Shionogi announce exclusive Option Agreement for Innovative Hearing Disorder treatment\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cilcare.com\/jp\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment - Cilcare\" \/>\n<meta property=\"og:description\" content=\"Cilcare and Shionogi announce exclusive Option Agreement for Innovative Hearing Disorder treatment\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cilcare.com\/jp\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Cilcare\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-06T06:22:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Deal-website.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"marie.peytavy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"marie.peytavy\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/\",\"url\":\"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/\",\"name\":\"Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment - Cilcare\",\"isPartOf\":{\"@id\":\"https:\/\/www.cilcare.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Deal-website.png\",\"datePublished\":\"2024-06-06T06:22:22+00:00\",\"author\":{\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/345b0ccb59d96b17a6908a76cad8e256\"},\"description\":\"Cilcare and Shionogi announce exclusive Option Agreement for Innovative Hearing Disorder treatment\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#primaryimage\",\"url\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Deal-website.png\",\"contentUrl\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Deal-website.png\",\"width\":1080,\"height\":1080,\"caption\":\"Shionogi Cilcare agreement\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cilcare.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cilcare.com\/#website\",\"url\":\"https:\/\/www.cilcare.com\/\",\"name\":\"Cilcare\",\"description\":\"Making hearing a priority\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cilcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/345b0ccb59d96b17a6908a76cad8e256\",\"name\":\"marie.peytavy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5de15f4de6ecabd3b374a0d5608780aae06de6510a1b70c8fdf69e014f99cfbc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5de15f4de6ecabd3b374a0d5608780aae06de6510a1b70c8fdf69e014f99cfbc?s=96&d=mm&r=g\",\"caption\":\"marie.peytavy\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment - Cilcare","description":"Cilcare and Shionogi announce exclusive Option Agreement for Innovative Hearing Disorder treatment","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cilcare.com\/jp\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/","og_locale":"ja_JP","og_type":"article","og_title":"Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment - Cilcare","og_description":"Cilcare and Shionogi announce exclusive Option Agreement for Innovative Hearing Disorder treatment","og_url":"https:\/\/www.cilcare.com\/jp\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/","og_site_name":"Cilcare","article_published_time":"2024-06-06T06:22:22+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Deal-website.png","type":"image\/png"}],"author":"marie.peytavy","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"marie.peytavy","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/","url":"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/","name":"Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment - Cilcare","isPartOf":{"@id":"https:\/\/www.cilcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Deal-website.png","datePublished":"2024-06-06T06:22:22+00:00","author":{"@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/345b0ccb59d96b17a6908a76cad8e256"},"description":"Cilcare and Shionogi announce exclusive Option Agreement for Innovative Hearing Disorder treatment","breadcrumb":{"@id":"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#primaryimage","url":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Deal-website.png","contentUrl":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2024\/06\/Deal-website.png","width":1080,"height":1080,"caption":"Shionogi Cilcare agreement"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cilcare.com\/2024\/06\/06\/cilcare-and-shionogi-announce-exclusive-option-agreement-for-innovative-hearing-disorder-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cilcare.com\/"},{"@type":"ListItem","position":2,"name":"Cilcare and Shionogi announce exclusive Option Agreement for innovative hearing disorder treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.cilcare.com\/#website","url":"https:\/\/www.cilcare.com\/","name":"Cilcare","description":"Making hearing a priority","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cilcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/345b0ccb59d96b17a6908a76cad8e256","name":"marie.peytavy","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5de15f4de6ecabd3b374a0d5608780aae06de6510a1b70c8fdf69e014f99cfbc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5de15f4de6ecabd3b374a0d5608780aae06de6510a1b70c8fdf69e014f99cfbc?s=96&d=mm&r=g","caption":"marie.peytavy"}}]}},"_links":{"self":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/12446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/comments?post=12446"}],"version-history":[{"count":24,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/12446\/revisions"}],"predecessor-version":[{"id":12474,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/12446\/revisions\/12474"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media\/12452"}],"wp:attachment":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media?parent=12446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/categories?post=12446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/tags?post=12446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}